SCHEMBL4111925

SCHEMBL4111925

CC(C)(C)OC(=O)N1CCC(OCc2noc(-c3ccc4ncsc4c3)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.49
CPT2 P23786 1/20 0.47
CPT1A P50416 1/20 0.47
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
DYRK2 Q92630 3/20 0.45
CLK2 P49760 1/20 0.45
CLK3 P49761 1/20 0.45
GSK3B P49841 1/20 0.45
DYRK1A Q13627 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
DYRK1B Q9Y463 1/20 0.45
CETP P11597 2/20 0.43
USP30 Q70CQ3 1/20 0.42
TBK1 Q9UHD2 3/20 0.42
IKBKE Q14164 1/20 0.41
CHEK2 O96017 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13693039 0.87 GPR119 (0.49) GPR119CETPTBK1IKBKECHEK2
SCHEMBL4101509 0.86 PIK3CA (0.53) GPR119CETPTBK1IKBKECHEK2
SCHEMBL4106521 0.83 GPR119 (0.50) GPR119CPT2CPT1ACETPUSP30
SCHEMBL12548315 0.82 GPR119 (0.57) GPR119CETP
SCHEMBL13602338 0.82 GPR119 (0.56) GPR119CETPUSP30CHEK2
SCHEMBL4418527 0.81 GPR119 (0.58) GPR119CETP
SCHEMBL4102957 0.81 GPR119 (0.56) GPR119CPT2CPT1ACETPUSP30
SCHEMBL4113375 0.81 GPR119 (0.52) GPR119CETPUSP30TBK1IKBKE
SCHEMBL4415816 0.81 CETP (0.55) GPR119CPT2CPT1ACETP
SCHEMBL4419641 0.81 GPR119 (0.54) GPR119CETPUSP30TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221644-A1 Gpcr Agonists PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221644-A1 Gpcr Agonists PROSIDION LIMITED (GB) 2009-09-03 US disclosed
US-20090221644-A1 Gpcr Agonists PROSIDION LIMITED (GB) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221644-A1 Gpcr Agonists GPR119, GCGR, GPR27 GPR119 1/4885CPT2 1381/4885CPT1A 631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.